<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61922">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01710436</url>
  </required_header>
  <id_info>
    <org_study_id>RDPAC2012</org_study_id>
    <nct_id>NCT01710436</nct_id>
  </id_info>
  <brief_title>Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype</brief_title>
  <acronym>RDPAC</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Institute &amp; Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Institute &amp; Fuwai Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, observational study to estimate the relationship between dosage
      of clopidogrel and platelet aggregation in Chinese with different genotype. The
      investigators suppose both pretreatment dosage of clopidogrel before  percutaneous coronary
      intervention (PCI) and CYP2C19 genotype may effect the platelet aggregation as well as
      clinical outcome.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change from Baseline in platelet aggregation</measure>
    <time_frame>1 month and 6 months after PCI</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events (MACE); Bleeding events</measure>
    <time_frame>6 months after PCI</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">880</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Low dose - Wild genotype (LW)</arm_group_label>
    <description>75mg Qd &gt; 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose - Variant genotype (LV)</arm_group_label>
    <description>75mg Qd &gt; 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose - Wild genotype (HW)</arm_group_label>
    <description>300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose - Variant genotype (HV)</arm_group_label>
    <description>300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese coronary heart disease (CHD) patient
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  accept PCI in Chinese CHD patients

          -  expected dual antiplatelet therapy (DAPT) at least 6 months

        Exclusion Criteria:

          -  another planned PCI within 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fu Wai Hospital, CAMS &amp; PUMC</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 16, 2013</lastchanged_date>
  <firstreceived_date>October 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiovascular Institute &amp; Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Xiaoxing Zhang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
